Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 20/20 | 0.82 |
| ▸ | OPRM1 | P35372 | 19/20 | 0.82 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21337554 | 0.95 | SIGMAR1 (0.76) | SIGMAR1OPRM1KCNH2 | |
| SCHEMBL18458744 | 0.95 | SIGMAR1 (0.88) | SIGMAR1OPRM1KCNH2 | |
| SCHEMBL18426649 | 0.94 | SIGMAR1 (0.89) | SIGMAR1OPRM1KCNH2 | |
| SCHEMBL18458285 | 0.91 | SIGMAR1 (1.00) | SIGMAR1OPRM1KCNH2 | |
| SCHEMBL18425860 | 0.90 | SIGMAR1 (0.87) | SIGMAR1OPRM1KCNH2 | |
| SCHEMBL18458336 | 0.90 | SIGMAR1 (0.87) | SIGMAR1OPRM1KCNH2 | |
| SCHEMBL20599025 | 0.89 | SIGMAR1 (0.79) | SIGMAR1OPRM1KCNH2 | |
| SCHEMBL20599127 | 0.89 | SIGMAR1 (0.75) | SIGMAR1OPRM1KCNH2 | |
| SCHEMBL18426783 | 0.88 | SIGMAR1 (1.00) | SIGMAR1OPRM1KCNH2 | |
| SCHEMBL20598968 | 0.87 | SIGMAR1 (0.72) | SIGMAR1OPRM1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3328853-B1 | SUBSTITUTED AMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS SA (ES) | 2019-09-11 | — | — | EP | claimed |
| US-10428051-B2 | Substituted amide derivatives having multimodal activity against pain | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-10-01 | — | — | US | disclosed |
| US-20190002443-A1 | SUBSTITUTED AMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-01-03 | — | — | US | disclosed |
| WO-2017016669-A1 | SUBSTITUTED AMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428051-B2 | Substituted amide derivatives having multimodal activity against pain | OPRM1, OPRD1, OPRK1 | SIGMAR1 5/4885OPRM1 1/4885KCNH2 1091/4885 |
| US-20190002443-A1 | SUBSTITUTED AMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | OPRM1, OPRD1, OPRK1 | SIGMAR1 5/4885OPRM1 1/4885KCNH2 1091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.